Motus GI, a medical technology company focussing on colonoscopy, has announced the first commercial placements of its Pure-Vu System as part of its initial U.S. market launch targeting early adopter hospitals.
Sreeram Parupudi, professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine at The University of Texas Medical Branch (UTMB), said: “The Pure-Vu System allows us to complete colonoscopy procedures that would have otherwise been delayed or cancelled due to insufficient bowel prep. The positive impact the Pure-Vu System can have on quality patient care, coupled with a reduction in length of stay for inpatients is exciting.”
The system is an FDA cleared medical device aimed to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The device integrates with standard and slim colonoscopes aiming to enable safe and rapid cleansing during the procedure while preserving established procedural workflow and techniques.
Tim Moran, chief executive officer of Motus GI, said: “Execution of our commercial strategy for the Pure-Vu System continues to progress as planned and we are excited to have started placing our Pure-Vu System at targeted sites as part of the initial U.S. market launch. Feedback from physicians and their staff members has been overwhelmingly supportive.
“The U.S. hospital inpatient colonoscopy market is comprised of approximately 1.5 million annual procedures, many of which can be delayed or cancelled. We believe the Pure-Vu System can reduce costs associated with delayed and repeat procedures, as well as extended hospitalisation stays due to insufficient bowel prep. To support the methodical commercial roll-out of our Pure-Vu System, we continue to strengthen our sales organisation with the addition of seasoned medical device sales professionals, strategically expanding our footprint and reach to key target hospital accounts that can become strong reference customers going forward.”
